Glycated ACE2 reduces anti-remodeling effects of renin-angiotensin system inhibition in human diabetic hearts.
Diabetes
Diabetic cardiomyopathy
HbA1c
Heart transplantation
RAS-inhibition therapy
Journal
Cardiovascular diabetology
ISSN: 1475-2840
Titre abrégé: Cardiovasc Diabetol
Pays: England
ID NLM: 101147637
Informations de publication
Date de publication:
05 08 2022
05 08 2022
Historique:
received:
19
04
2022
accepted:
15
07
2022
entrez:
5
8
2022
pubmed:
6
8
2022
medline:
10
8
2022
Statut:
epublish
Résumé
High glycated-hemoglobin (HbA1c) levels correlated with an elevated risk of adverse cardiovascular outcomes despite renin-angiotensin system (RAS) inhibition in type-2 diabetic (T2DM) patients with reduced ejection fraction. Using the routine biopsies of non-T2DM heart transplanted (HTX) in T2DM recipients, we evaluated whether the diabetic milieu modulates glycosylated ACE2 (GlycACE2) levels in cardiomyocytes, known to be affected by non-enzymatic glycosylation, and the relationship with glycemic control. We investigated the possible effects of GlycACE2 on the anti-remodeling pathways of the RAS inhibitors by evaluating the levels of Angiotensin (Ang) 1-9, Ang 1-7, and Mas receptor (MasR), Nuclear-factor of activated T-cells (NFAT), and fibrosis in human hearts. We evaluated 197 first HTX recipients (107 non-T2DM, 90 T2DM). All patients were treated with angiotensin-converting enzyme inhibitor (ACE-I) or angiotensin receptor blocker (ARB) at hospital discharge. Patients underwent clinical evaluation (metabolic status, echocardiography, coronary CT-angiography, and endomyocardial biopsies). Biopsies were used to evaluate ACE2, GlycACE2, Ang 1-9, Ang 1-7, MasR, NAFT, and fibrosis. GlycACE2 was higher in T2DM compared tonon-T2DM cardiomyocytes. Moreover, reduced expressions of Ang 1-9, Ang 1-7, and MasR were observed, suggesting impaired effects of RAS-inhibition in diabetic hearts. Accordingly, biopsies from T2DM recipients showed higher fibrosis than those from non-T2DM recipients. Notably, the expression of GlycACE2 in heart biopsies was strongly dependent on glycemic control, as reflected by the correlation between mean plasma HbA1c, evaluated quarterly during the 12-month follow-up, and GlycACE2 expression. Poor glycemic control, favoring GlycACE2, may attenuate the cardioprotective effects of RAS-inhibition. However, the achievement of tight glycemic control normalizes the anti-remodeling effects of RAS-inhibition. https://clinicaltrials.gov/ NCT03546062.
Sections du résumé
BACKGROUND
High glycated-hemoglobin (HbA1c) levels correlated with an elevated risk of adverse cardiovascular outcomes despite renin-angiotensin system (RAS) inhibition in type-2 diabetic (T2DM) patients with reduced ejection fraction. Using the routine biopsies of non-T2DM heart transplanted (HTX) in T2DM recipients, we evaluated whether the diabetic milieu modulates glycosylated ACE2 (GlycACE2) levels in cardiomyocytes, known to be affected by non-enzymatic glycosylation, and the relationship with glycemic control.
OBJECTIVES
We investigated the possible effects of GlycACE2 on the anti-remodeling pathways of the RAS inhibitors by evaluating the levels of Angiotensin (Ang) 1-9, Ang 1-7, and Mas receptor (MasR), Nuclear-factor of activated T-cells (NFAT), and fibrosis in human hearts.
METHODS
We evaluated 197 first HTX recipients (107 non-T2DM, 90 T2DM). All patients were treated with angiotensin-converting enzyme inhibitor (ACE-I) or angiotensin receptor blocker (ARB) at hospital discharge. Patients underwent clinical evaluation (metabolic status, echocardiography, coronary CT-angiography, and endomyocardial biopsies). Biopsies were used to evaluate ACE2, GlycACE2, Ang 1-9, Ang 1-7, MasR, NAFT, and fibrosis.
RESULTS
GlycACE2 was higher in T2DM compared tonon-T2DM cardiomyocytes. Moreover, reduced expressions of Ang 1-9, Ang 1-7, and MasR were observed, suggesting impaired effects of RAS-inhibition in diabetic hearts. Accordingly, biopsies from T2DM recipients showed higher fibrosis than those from non-T2DM recipients. Notably, the expression of GlycACE2 in heart biopsies was strongly dependent on glycemic control, as reflected by the correlation between mean plasma HbA1c, evaluated quarterly during the 12-month follow-up, and GlycACE2 expression.
CONCLUSION
Poor glycemic control, favoring GlycACE2, may attenuate the cardioprotective effects of RAS-inhibition. However, the achievement of tight glycemic control normalizes the anti-remodeling effects of RAS-inhibition.
TRIAL REGISTRATION
https://clinicaltrials.gov/ NCT03546062.
Identifiants
pubmed: 35932065
doi: 10.1186/s12933-022-01573-x
pii: 10.1186/s12933-022-01573-x
pmc: PMC9356400
doi:
Substances chimiques
Angiotensin Receptor Antagonists
0
Angiotensin-Converting Enzyme Inhibitors
0
Glycated Hemoglobin A
0
Peptide Fragments
0
Peptidyl-Dipeptidase A
EC 3.4.15.1
Angiotensin-Converting Enzyme 2
EC 3.4.17.23
Banques de données
ClinicalTrials.gov
['NCT03546062']
Types de publication
Clinical Trial
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
146Informations de copyright
© 2022. The Author(s).
Références
Ann Intern Med. 2004 Sep 21;141(6):421-31
pubmed: 15381515
J Biol Chem. 2001 Feb 2;276(5):3524-30
pubmed: 11044444
Circulation. 2002 Sep 3;106(10):1251-5
pubmed: 12208801
J Am Coll Cardiol. 2020 Feb 11;75(5):525-538
pubmed: 32029136
J Endocr Soc. 2019 Jul 10;3(10):1799-1818
pubmed: 31528827
Circ Res. 2012 May 11;110(10):1322-35
pubmed: 22474255
Circ Heart Fail. 2016 Jan;9(1):
pubmed: 26754626
Diabetes Care. 2018 Jan;41(Suppl 1):S13-S27
pubmed: 29222373
J Am Coll Cardiol. 2012 Feb 21;59(8):739-47
pubmed: 22340266
Nutr Metab (Lond). 2018 Oct 10;15:72
pubmed: 30337945
J Am Coll Cardiol. 2020 Mar 24;75(11):1249-1262
pubmed: 32192650
Circulation. 2006 Aug 8;114(6):597-605
pubmed: 16894049
Nature. 2000 Apr 13;404(6779):787-90
pubmed: 10783895
Eur J Heart Fail. 2014 Mar;16(3):325-33
pubmed: 24464788
Eur Heart J. 2016 Jan 1;37(1):67-119
pubmed: 26320113
Circ Res. 2018 Feb 16;122(4):624-638
pubmed: 29449364
Eur Heart J Cardiovasc Imaging. 2015 Sep;16(9):919-48
pubmed: 26139361
Eur Heart J. 2000 Dec;21(23):1967-78
pubmed: 11071803
Sci Rep. 2015 Mar 05;5:8794
pubmed: 25740572
Circ Heart Fail. 2014 Mar 1;7(2):327-39
pubmed: 24389129
Am J Physiol Heart Circ Physiol. 2008 Apr;294(4):H1675-84
pubmed: 18296558
Am J Hypertens. 1998 Feb;11(2):137-46
pubmed: 9524041
Biol Res. 2021 Aug 3;54(1):23
pubmed: 34344467
J Am Coll Cardiol. 2021 Apr 13;77(14):1731-1743
pubmed: 33832600
Cardiovasc Diabetol. 2021 May 7;20(1):99
pubmed: 33962629
Diabetes Care. 2018 Jun;41(6):1285-1291
pubmed: 29626073
Curr Hypertens Rep. 2015 Jan;17(1):506
pubmed: 25432898
Epigenetics. 2017 Jun 3;12(6):401-415
pubmed: 28059593